Cytiva Acquires Chromatography Resins Manufacturing Facility in Muskegon, Michigan
Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment.
Cytiva announced on July 13, 2022 that it had acquired a new manufacturing facility in Muskegon, MI. The new facility, a chromatography resins manufacturing site, is part of Cytiva and Pall Corporation's $1.5 billion capacity expansion investment, allowing Cytiva to expand its resin manufacturing beyond Sweden.
According to a company press release, Cytiva plans to renovate the site into a 168,000 ft² biomanufacturing center consisting of multiple buildings; it will house approximately 200 associates upon completion. With a planned construction start date in Q3 2022, manufacturing is expected to begin in 2026.
“When you’re looking to help provide global biotechnology solutions to the world, it requires you to be nimble and flexible,” said Emmanuel Ligner, Danaher Group Executive, president and CEO, Cytiva, in the press release. “By investing in Muskegon, Michigan, we will be closer to our North American customers, who are developing advanced biotherapeutics.”
Source: Cytiva
British Patient Capital Invests £10 Million in Maxion Therapeutics, Part of Series A Financing Round
March 27th 2025The £10 million (US$13 million) investment is part of a larger £58 million (US$75 million) Series A financing round to be used for the development of Maxion Therapeutics’ preclinical lead program for treating inflammatory diseases.
